MA54200B1 - Procédé industriel pour la préparation d'estétrol de pureté élevée - Google Patents

Procédé industriel pour la préparation d'estétrol de pureté élevée

Info

Publication number
MA54200B1
MA54200B1 MA54200A MA54200A MA54200B1 MA 54200 B1 MA54200 B1 MA 54200B1 MA 54200 A MA54200 A MA 54200A MA 54200 A MA54200 A MA 54200A MA 54200 B1 MA54200 B1 MA 54200B1
Authority
MA
Morocco
Prior art keywords
estetrol
preparation
high purity
industrial process
formula
Prior art date
Application number
MA54200A
Other languages
English (en)
Other versions
MA54200A (fr
Inventor
Róbert Lovas
Sándor Mahó
Ildikó Bacsa
Beatrix Mayer
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MA54200A publication Critical patent/MA54200A/fr
Publication of MA54200B1 publication Critical patent/MA54200B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne la préparation d'estétrol de formule (i), des dérivés de ceux-ci protégés aux positions 3,15a, 16a, 17ß de formule générale (iii), et des dérivés 3-hydroxy de ceux-ci protégés aux positions 15a, 16a, 17ß de formule générale (iv), et des intermédiaires des formules générales (iii) et (iv) appliqués dans le procédé. Un autre aspect de l'invention concerne l'utilisation d'estétrol de formule (i) obtenu par le procédé de l'invention pour la préparation d'une composition pharmaceutique.
MA54200A 2019-09-03 2020-09-02 Procédé industriel pour la préparation d'estétrol de pureté élevée MA54200B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1900315A HU231240B1 (hu) 2019-09-03 2019-09-03 Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
PCT/IB2020/058148 WO2021044302A1 (fr) 2019-09-03 2020-09-02 Procédé industriel pour la préparation d'estétrol de pureté élevée

Publications (2)

Publication Number Publication Date
MA54200A MA54200A (fr) 2022-04-27
MA54200B1 true MA54200B1 (fr) 2023-02-28

Family

ID=89992977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54200A MA54200B1 (fr) 2019-09-03 2020-09-02 Procédé industriel pour la préparation d'estétrol de pureté élevée

Country Status (32)

Country Link
US (1) US11633406B2 (fr)
EP (1) EP3877395B1 (fr)
JP (1) JP7265087B2 (fr)
KR (1) KR102871606B1 (fr)
CN (1) CN114302889B (fr)
AU (1) AU2020343497B2 (fr)
CA (1) CA3147815C (fr)
CL (1) CL2022000492A1 (fr)
CO (1) CO2022003769A2 (fr)
CU (1) CU24692B1 (fr)
DK (1) DK3877395T3 (fr)
EC (1) ECSP22022403A (fr)
ES (1) ES2855923T3 (fr)
FI (1) FI3877395T3 (fr)
GE (1) GEP20247626B (fr)
HR (1) HRP20230230T1 (fr)
HU (2) HU231240B1 (fr)
IL (1) IL290973B2 (fr)
JO (1) JOP20220041A1 (fr)
LT (1) LT3877395T (fr)
MA (1) MA54200B1 (fr)
MD (1) MD3877395T2 (fr)
MX (1) MX2022002603A (fr)
MY (1) MY206905A (fr)
PE (1) PE20221418A1 (fr)
PH (1) PH12022550388A1 (fr)
PL (1) PL3877395T3 (fr)
PT (1) PT3877395T (fr)
RS (1) RS63966B1 (fr)
SI (1) SI3877395T1 (fr)
WO (1) WO2021044302A1 (fr)
ZA (1) ZA202203557B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112020004564T5 (de) * 2019-09-27 2022-06-15 Industriale Chimica S.R.L. VERFAHREN ZUM HERSTELLEN VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIEN-3,15,16,17-TETROL (ESTETROL) UND ZWISCHENSTUFEN DES VERFAHRENS
HU231651B1 (hu) * 2021-10-01 2025-05-28 Industriale Chimica S.R.L. Eljárás (15alfa,16alfa,17béta)-ösztra-1,3,5(10)-trién-3,15,16,17-tetrol (esztetrol) és esztetrol-monohidrát előállítására
JP2026503158A (ja) * 2023-02-02 2026-01-27 インダストリアーレ キミカ エッセ．エッレ．エッレ． （１５α，１６α，１７β）－エストラ－１，３，５（１０）－トリエン－３，１５，１６，１７－テトロール（エステトロール）一水和物の調製方法
CN117088928B (zh) * 2023-08-16 2025-09-09 湖北共同甾体药物研究院有限公司 用于制备高纯度雌四醇的工艺
CN119569803B (zh) * 2023-09-05 2025-09-16 秦皇岛紫竹药业有限公司 一种制备高纯度雌四醇的方法
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás
CN119112905B (zh) * 2024-09-10 2026-07-28 武汉九珑人福药业有限责任公司 含雌孕激素的药物组合物、药物制剂及其制备方法、应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (fr) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
DE60234515D1 (de) 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
SI1511496T1 (sl) 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
EP1526856B1 (fr) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Composition pharmaceutique comprenant des derives d'estetrol utilises dans la therapie anticancereuse
WO2004037269A1 (fr) 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Compositions pharmaceutiques comprenant des derives d'estetrol a utiliser dans le traitement du cancer
CN100343269C (zh) * 2002-11-08 2007-10-17 潘塔希生物科学股份有限公司 通过雌酮衍生的甾体化合物合成雌四醇
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
EP2383279A1 (fr) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
CA2843951C (fr) 2011-08-11 2019-08-06 Wout WOUTERS Utilisation d'estetrol comme contraceptif d'urgence
AU2012320423C1 (en) * 2011-10-07 2018-01-25 Estetra Srl Process for the production of estetrol
EP2653163A1 (fr) 2012-04-19 2013-10-23 Université de Liège Constituants estrogènes pour l'utilisation dans le traitement de troubles neurologiques
WO2013034780A2 (fr) * 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Procédé de préparation de l'estétrol et de composés analogues
ES2624667T3 (es) * 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
DK3079671T3 (en) 2013-12-12 2017-12-11 Donesta Bioscience B V Orally disintegrating solid dosage unit containing an estetrol component
EP3701944B1 (fr) 2015-06-18 2021-12-08 Estetra SRL Unité posologique orodispersible contenant un composant d'estétrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
SG11202000881VA (en) 2017-08-01 2020-02-27 Fund Sa Adjuvant therapy for use in prostate cancer treatment
IL276584B2 (en) 2018-02-07 2024-10-01 Estetra Srl Contraceptive composition with reduced cardiovascular effects
DE112020004564T5 (de) 2019-09-27 2022-06-15 Industriale Chimica S.R.L. VERFAHREN ZUM HERSTELLEN VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIEN-3,15,16,17-TETROL (ESTETROL) UND ZWISCHENSTUFEN DES VERFAHRENS

Also Published As

Publication number Publication date
FI3877395T3 (fi) 2023-03-18
MY206905A (en) 2025-01-15
DK3877395T3 (da) 2023-03-06
ES2855923T3 (es) 2023-04-28
GEP20247626B (en) 2024-05-27
RS63966B1 (sr) 2023-03-31
CO2022003769A2 (es) 2022-04-19
MD3877395T2 (ro) 2023-05-31
JP7265087B2 (ja) 2023-04-25
PT3877395T (pt) 2023-02-02
WO2021044302A1 (fr) 2021-03-11
HU231240B1 (hu) 2022-04-28
SI3877395T1 (sl) 2023-03-31
HRP20230230T1 (hr) 2023-04-14
EP3877395B1 (fr) 2022-12-07
BR112022003254A2 (pt) 2022-05-17
EP3877395A1 (fr) 2021-09-15
CU24692B1 (es) 2024-01-10
HUE061427T2 (hu) 2023-07-28
KR102871606B1 (ko) 2025-10-16
CN114302889A (zh) 2022-04-08
CL2022000492A1 (es) 2023-03-10
MX2022002603A (es) 2022-03-25
ZA202203557B (en) 2022-11-30
PE20221418A1 (es) 2022-09-20
MA54200A (fr) 2022-04-27
PH12022550388A1 (en) 2024-01-29
NZ786568A (en) 2026-01-30
AU2020343497B2 (en) 2023-02-02
LT3877395T (lt) 2023-02-27
AU2020343497A1 (en) 2022-04-14
US11633406B2 (en) 2023-04-25
KR20220071206A (ko) 2022-05-31
US20220296609A1 (en) 2022-09-22
ECSP22022403A (es) 2022-04-29
IL290973B1 (en) 2023-07-01
JP2022546016A (ja) 2022-11-02
PL3877395T3 (pl) 2023-05-08
CN114302889B (zh) 2023-08-29
HUP1900315A1 (hu) 2021-03-29
JOP20220041A1 (ar) 2023-01-30
ES2855923T1 (es) 2021-09-24
CA3147815A1 (fr) 2021-03-11
CA3147815C (fr) 2023-03-28
IL290973B2 (en) 2023-11-01
IL290973A (en) 2022-05-01
CU20220013A7 (es) 2022-10-11

Similar Documents

Publication Publication Date Title
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
PH12022550388A1 (en) Industrial process for the preparation of high purity estetrol
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
FR3091873B1 (fr) Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
JP2003513889A (ja) ノイラミニダーゼの阻害剤
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
DE69813571D1 (de) 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
MA34957B1 (fr) Derives heteroaryle a titre modulateurs des nachr alpha 7
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.
MX2020012691A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.
MA49560B1 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
BR0214842A (pt) Inibidores de integrase hiv
FR3091872B1 (fr) Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
BR0308837A (pt) Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i)
TN2011000211A1 (fr) Pyrrolidines
EP1831239B8 (fr) Procédé de synthèse de la gamma-lactone de l'acide 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bisméthylène -17 alpha- pregn-4- ène-3-one-21 carboxylique et intermédiaries-clés de ce procédé
ATE445589T1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
MA27195A1 (fr) Derives d'acyl-3 -carboxyphenyluree, procedes pour les preparer et leur utilisation.
Alexakis et al. Boron trifluoride assisted opening of epoxides by lithium alkenyl aluminate reagents
EA200801508A1 (ru) ВЫСОКОЧИСТЫЙ 17α-ЦИАНОМЕТИЛ-17β-ГИДРОКСИ-ЭСТРА-4,9-ДИЕН-3-ОН И СПОСОБ ЕГО СИНТЕЗА